MAS1 and Alzheimer disease: A loss of function of cerebral ACE2 is expected to reduce levels of Ang1-7 and MAS/G receptor activity, leading to a decrease in anti-inflammatory, anti-oxidant, vasodilatory, and neuroprotective properties[42], which is undesirable in AD [30].